Search results
Results from the WOW.Com Content Network
Gefapixant, sold under the brand name Lyfnua, is a medication used to treat chronic (long-term) cough. [1] It acts as an antagonist of the P2RX3 receptor. [2] [3] [4]
Merck's gefapixant works by blocking receptors that stimulate the nerves and trigger the urge to cough. The drug, which was given twice a day, was evaluated across two late-stage trials where a ...
The panel will deliberate whether the data provided by Merck establishes that a small reduction in cough frequency with the use of gefapixant is clinically meaningful to patients. US FDA staff ...
Its predecessor was the NHS Research & Development programme which was established in 1991. Factors influencing the creation of the NIHR were the growing importance of evidence-based medicine in science and policymaking, the spread of New Public Management thinking and increased government funding.
The British National Formulary (BNF) is a United Kingdom (UK) pharmaceutical reference book that contains a wide spectrum of information and advice on prescribing and pharmacology, along with specific facts and details about many medicines available on the UK National Health Service (NHS).
Guaifenesin/codeine is a fixed-dose combination cold medicine used for the treatment of cough. [1] It contains guaifenesin, an expectorant; and codeine, as the phosphate, an opioid antitussive. [1]
Pentoxyverine or carbetapentane is an antitussive (cough suppressant) commonly used for cough associated with illnesses like common cold.It is sold over-the-counter as Solotuss, [1] or in combination with other medications, especially decongestants.
Approved indication for dihydrocodeine is the management of moderate to moderately severe pain as well as coughing and shortness of breath. As is the case with other drugs in this group, the antitussive dose tends to be less than the analgesic dose, and dihydrocodeine is a powerful cough suppressant like all other members of the immediate codeine family (see below) and their cousins ...